The QualityStocks Daily Friday, June 25th, 2021

Today's Top 3 Investment Newsletters

BUYINS.NET(IKNX) $18.5600 +64.25%

Tip.us(GIGL) $0.0590 +63.43%

QualityStocks(CYBNY) $0.7200 +53.19%

The QualityStocks Daily Stock List

Virios Therapeutics (VIRI)

RedChip reported earlier on Virios Therapeutics (VIRI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Virios Therapeutics Inc. (NASDAQ: VIRI) is a development stage biotechnology firm that is engaged in the development and commercialization of antiviral treatments for ailments linked to viral triggered abnormal immune responses.

The firm has its headquarters in Alpharetta, Georgia and was incorporated in 2012, on February 28th by William L. Pridgen. Prior to its name change in December 2020, the firm was known as Virious Therapeutics LLC. It operates in the health care sector, under the biotech and pharma sub-industry and serves consumers in the U.S.

The company’s objective is to enhance patient outcomes by finding the underlying cause of fibromyalgia as well as other conditions. Scientists propose that the overactive immune responses associated with activation of HSV-1 (Herpes Simplex Virus-1) tissue may be a possible cause of chronic ailments like functional somatic syndrome, chronic fatigue syndrome, irritable bowel disease and fibromyalgia. All these diseases are characterized by a waning and waxing manifestation of illness.

The enterprise’s lead drug candidate is a fixed dose combination of celecoxib and famciclovir known as IMC-1, which has been indicated for the treatment of fibromyalgia. Its end goal is to decrease viral-mediated illness burdens. The candidate is currently undergoing a phase 2b clinical trial, which is expected to end by the first quarter of 2022.

The firm’s IMC-1 candidate was recently awarded fast track designation by the FDA. The candidate, which has shown promising results, may soon be introduced to the market, which will not only benefit the patients who suffer from fibromyalgia but also bring in more investors into the firm.

Virios Therapeutics (VIRI), closed Friday's trading session at $6.59, off by 2.6588%, on 33,626 volume with 259 trades. The average volume for the last 3 months is 165,981 and the stock's 52-week low/high is $4.5999999/$16.709999.

Cellectar Biosciences (CLRB)

StockMarketWatch, PCG Advisory, MarketClub Analysis, QualityStocks, InvestorPlace, TraderPower, MarketBeat, Wall Street Resources, Jason Bond, SeeThruEquity Research, StreetInsider, BUYINS.NET, OTC Markets Group, Marketbeat.com, Wall Street Mover, Schaeffer's, Wealth Insider Alert, Stock Beast, Stock Market Watch, Stock News Now and Investing Futures reported earlier on Cellectar Biosciences (CLRB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cellectar Biosciences Inc. (NASDAQ: CLRB) (FRA: NV4P) is a clinical biopharmaceutical firm that is engaged in discovering, developing and commercializing therapies for treating cancer.

The firm has its headquarters in Florham Park, New Jersey and was incorporated in June 1996. It operates in the health care sector, under the biotech and pharma sub-industry. The firm is party to collaborative PDC programs with Orano Med and Avicenna Oncology GMBH, which entails the development of the CLR 12120 Series and the CLR 2000 Series.

The company is focused on developing targeted phospholipid drug conjugates for imaging and treating cancer. Its pipeline is made of clinical and pre-clinical product candidates, which include chemotherapeutic and radio-therapeutic phospholipid drug conjugates.

The enterprise’s product candidates include a phospholipid drug conjugate (PDC) chemotherapeutic program dubbed CLR1900, which is in its pre-clinical stage for the treatment of solid tumors; a PDC dubbed CLR 131, which is currently in its phase 1 study for treating refractory and relapse multiple myeloma, neck and head cancers and pediatric cancers; a phase 2b study for patients with refractory and relapsed multiple myeloma and phase 2 clinical trial for patients with refractory or relapsed B-cell malignancies and Waldenstrom's macroglobulinemia. The enterprise provides its products to the healthcare, pharmaceutical and medical industries. In addition to this, the enterprise also develops CLR 1502. CLR 124, CLR 125, CTX CLR 1700, CTX CLR 1602-PTX and CTX CLR 1800-P.

The firm recently presented data from its CLR 131 Waldenstrom's macroglobulinemia clinical trial, which show 100% overall response rate and mean treatment free remission. If successful, the formulation which has the potential to help patients with multi-drug refractoriness in the above disease and also improve the quality of life, will not only offer patients better treatment and prolong their lives but also encourage more investments into the firm, which will be good for the company’s growth.

Cellectar Biosciences (CLRB), closed Friday's trading session at $1.27, up 3.252%, on 1,267,788 volume with 4,060 trades. The average volume for the last 3 months is 586,523 and the stock's 52-week low/high is $1.00999999/$2.98000001.

Gaucho Group Holdings (VINO)

QualityStocks and MarketClub Analysis reported earlier on Gaucho Group Holdings (VINO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gaucho Group Holdings Inc. (NASDAQ: VINO) is a holding firm that is focused on investing in, developing and operating real estate projects in Argentina.

The firm has its headquarters in Miami Beach, Florida and was founded in 1999, on April 5th by Scot L. Mathis. Prior to its name change in March 2019, the firm was known as Algodon Group Inc. It operates in the real estate sector, under the real estate owners and developers’ plus sub-developers’ sub-industry. The firm serves consumers in Argentina as well as in the U.S.

The company identifies and develops investments in the luxury property, hospitality and boutique hotels markets as well in the other lifestyle businesses, like real estate development, tennis, golf and wine production and distribution. It conducts its business in Argentina through Algodon Wine Estates S.R.L, Algodon Properties II S.R.L., the Algodon Recoleta S.R.L., Algodon Global Properties LLC and InvestProperty Group LLC.

The enterprise also operates and owns subdivided property for residential development, a winery and golf resort with hotel, dining and tennis court amenities known as Algodon Wine Estates, which is located in Mendoza and a luxury boutique hotel located in Buenos Aires known as Algodon Mansion. The company distributes wines in Europe via its UK entity and also sells and distributes accessories and high-end luxury fashion products via an e-commerce platform.

The firm recently launched its Amazon Storefront in Buenos Aires, which will enable them to expand their global profile while allowing them to reach more consumers, which will increase the firm’s revenue while also bringing more investors into the firm.

Gaucho Group Holdings (VINO), closed Friday's trading session at $5.34, off by 7.2917%, on 447,138 volume with 2,091 trades. The average volume for the last 3 months is 1.048M and the stock's 52-week low/high is $3.00/$21.4500007.

Intec Pharma (NTEC)

MarketClub Analysis, Schaeffer's, MarketBeat, TraderPower, Top Pros' Top Picks, BUYINS.NET, StockMarketWatch, Zacks, Wealth Insider Alert, The Online Investor, StreetInsider, InvestorPlace, Equities.com and Barchart reported earlier on Intec Pharma (NTEC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Intec Pharma Ltd. (NASDAQ: NTEC) is a clinical stage biopharmaceutical firm that is engaged in the development of drugs that are based off of its proprietary gastric retention technology.

The firm has its headquarters in Jerusalem, Israel and was incorporated in 2000, on October 23rd by Zvika Joseph. Prior to its name change in March 2004, the firm was known as Intec Pharmaceuticals Ltd. It operates as part of the scientific research and development services industry under the healthcare sector in the biotech and pharma sub-industry. The firm serves consumers in the United States.

The enterprise is party to a CBD research collaboration agreement and a research collaboration agreement with GW Research Limited and Merck Sharp & Dohme respectively. Its efforts are directed to its clinical trials as well as research and development. It develops drug formulations through the use of its Accordion Pill platform technology, which has been designed to enhance the safety and effectiveness of drugs that are currently being developed by using an efficient and specific gastric retention and release mechanism.

The enterprise’s product pipeline is made up of AP-CBD, AP-THC and AP-THC/CBD, which are indicated for various pain indications; Accordion Pill Zaleplon, which is undergoing a phase three clinical trial to test its effectiveness as a treatment for insomnia as well as small bowel and gastroduodenal NSAID induced ulcers. In addition to this, the company develops the Accordion Pill Carbidopa/Levodopa, which is indicated for treating Parkinson’s disease symptoms.

The firm’s Merck Sharp & Dohme cannabinoid research collaboration agreement may soon bring in hefty returns, given the popularity of the marijuana market and its legalization across the country, as well as bringing in more investors into the firm.

Intec Pharma (NTEC), closed Friday's trading session at $3.57, up 1.4205%, on 681,237 volume with 2,424 trades. The average volume for the last 3 months is 1.214M and the stock's 52-week low/high is $2.20000004/$15.8159999.

Newpark Resources (NR)

Zacks, SmarTrend Newsletters, Marketbeat.com, MarketBeat, QualityStocks, StreetInsider, StreetAuthority Daily, The Best Newsletters, Energy and Capital, Market FN, Stock Research Newsletter, TopStockAnalysts, AnotherWinningTrade, Bull Warrior Stocks, InvestorPlace, INO.com Market Report, MarketClub Analysis, Daily Trade Alert, BUYINS.NET, Penny Invest, Penny Sleuth, SmallCapVoice, StockEgg, StockMarketWatch, The Street, TheStockAdvisors, Trades Of The Day, Trading Concepts, Wyatt Investment Research and SmallCapNetwork reported earlier on Newpark Resources (NR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Newpark Resources Inc. (NYSE: NR) (FRA: NWP) is focused on supplying products, services and rentals mainly to the production and natural gas and oil exploration industry.

The firm has its headquarters in the Woodlands, Texas and was incorporated in 1932. It operates in the energy sector, under the oil and gas industry, in the oil and gas services and equipment sub-industry.

The company operates through the Mats and Integrated services, Industrial solutions and Fluid systems segments. The former segment is made up of site construction, composite mat rentals and related site services for consumers in the construction, petrochemical, solar, pipeline, electrical distribution and transmission and gas and oil production and exploration industries while the fluid segment provides technical services and drilling fluid products for technical drilling projects that involve complex subsurface conditions to consumers in some countries in Latin America and Asia Pacific as well as in Africa, the Middle East, Europe and North America. On the other hand, the industrial solutions segment involves the provision of composite matting system rentals which are used for temporary worksite access. This is in addition to selling composite mats to consumers across the globe and engaging in the provision of site restoration, erosion control, fluids and spill containment, environmental protection, site planning and preparation and access road construction services.

The firm recently received a total satisfaction award in the EnergyPoint Research 2021 Oilfield Services Customer Satisfaction Survey, which attests to the firm’s award-winning customer service. This may help bring in more investors into the firm, which will in turn boost growth.

Newpark Resources (NR), closed Friday's trading session at $3.7, off by 5.6122%, on 1,430,743 volume with 3,333 trades. The average volume for the last 3 months is 639,721 and the stock's 52-week low/high is $0.699999988/$4.07999992.

Rezolute, Inc. (RZLT)

QualityStocks, MarketBeat, FreeRealTime and BUYINS.NET reported earlier on Rezolute, Inc. (RZLT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rezolute, Inc. is a clinical stage biopharmaceutical company headquartered in Louisville, Colorado. It specializes in the development of innovative drug therapies for metabolic and orphan diseases. The Company formerly went by the name AntriaBio, Inc. It changed its corporate name to Rezolute, Inc. in December of 2017. Rezolute’s shares trade on the OTC Markets Group’s OTCQB.

Rezolute is advancing a divers pipeline. This pipeline includes RZ358 (Phase 2). This is an antibody for the ultra-orphan indication of Congenital HyperInsulinism (CHI), with an abbreviated path-to-market strategy. In addition, the pipeline includes AB101 (Phase 1). This is a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management through reducing the therapeutic burden for patients and improving compliance.

The Company’s pipeline also includes a Plasma Kallikrein Inhibitor (PKI) portfolio with two lead compounds. One is RZ402 targeting Diabetic Macular Edema (DME). The other is RZ602 targeting Hereditary Angioedema (HAE), an orphan indication.

Rezolute and XOMA Corporation have executed a license agreement. The agreement provides Rezolute with the exclusive international rights to develop and commercialize RZ358 (formerly XOMA 358) for Congenital Hyperinsulinism (CHI), an ultra-orphan indication. XOMA is a pioneer in the discovery, development, as well as licensing of therapeutic antibodies.

RZ358 is a first-in-class fully human monoclonal antibody. It counteracts the effects of elevated insulin via allosteric modulation of the insulin receptor. This makes it well-suited as a therapy for severe, persistent hypoglycemia caused by hyperinsulinemic conditions such as CHI.

Rezolute, Inc. (RZLT), closed Friday's trading session at $15.99, up 25.1174%, on 247,513 volume with 1,659 trades. The average volume for the last 3 months is 64,154 and the stock's 52-week low/high is $5.86000013/$24.0499992.

Worlds, Inc. (WDDD)

QualityStocks, TopPennyStockMovers and Barchart reported earlier on Worlds, Inc. (WDDD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Worlds, Inc. is a foremost Intellectual Property (IP) developer and licensee of patents related to three-dimensional (3D) online virtual worlds. The Company has a portfolio of 10 U.S. patents for multi-server technology for 3D applications. Worlds designs and develops software, content, and also related technology for the creation of interactive 3D Internet Websites.

The design of its 3D Internet sites are to enable visitation by users through providing them with online communities featuring diverse content, information content, and interactive capabilities. Established in 1994, Worlds is based in Brookline, Massachusetts. Worlds, Inc. was formerly known as Worlds.com, Inc. Worlds’ shares trade on the OTC Markets Group’s OTCQB.

The earliest of the above-mentioned patents issued on an application filed November 12, 1996. A provisional patent application, serial number 60/020,296, was filed on November 13, 1995. These patents are related to each other. They disclose and claim systems and methods for enabling users to interact in a virtual space.

The Company has developed patented 3D technology that provide 3D multi-user environments, known as "virtual worlds," that have interactive Avatars, rich media graphics, text chat, voice-to-voice chat, video, and e-commerce. The 3D communities enable visitors to interact with each other, teleport throughout the Worlds environment, and participate in shared experiences.

Worlds recently announced that it filed a complaint for patent infringement against Microsoft Corporation. In the complaint, Worlds accuses Microsoft and its “Minecraft” video game product of infringing Worlds' U.S. Patent No. 8,082,501, titled “System and Method for Enabling Users to Interact in a Virtual Space” (the ’501 Patent).

Mr. Thom Kidrin, Worlds, Inc. Chief Executive Officer, said, “Our ’501 Patent is a fundamental building block to the functionality and success of numerous 3-D, computer-generated, multi-user, interactive virtual world systems and games that have been developed over multiple years and are enjoyed by millions of people globally. While we are excited by the popularity of these games, we want to ensure that we and our shareholders receive just compensation for the system and method we developed that helped make these types of products possible.”

Worlds, Inc. (WDDD), closed Friday's trading session at $0.11805, up 22.395%, on 520,038 volume with 90 trades. The average volume for the last 3 months is 293,292 and the stock's 52-week low/high is $0.029999999/$0.709999978.

Grom Social Enterprises, Inc. (GROM)

QualityStocks and Jason Bond reported earlier on Grom Social Enterprises, Inc. (GROM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Grom Social Enterprises, Inc., by way of its subsidiaries, operates a social media network designed for children in the USA. Fundamentally, the Company is the developer of Grom Social, a top social media platform for kids. In addition, it is an original children’s entertainment content provider. Grom provides these for children 13 years of age and under. The Company provides safe and secure digital environments for kids that can be monitored by their parents or guardians. Grom Social Enterprises is based in Boca Raton, Florida. The Company lists on the OTC Markets’ OTCQB.

Grom Social Enterprises has a number of operating subsidiaries. These include the above-mentioned Grom Social, which delivers its content via mobile and desktop environments (web portal and apps), which entertain children, let them interact with friends, access relevant news, and play proprietary games. This is while teaching them about being a good digital citizen. The Company’s emphasis here is making the internet safe for kids through teaching and monitoring, giving parents the tools they need for peace of mind.

In addition, Grom owns and operates Top Draw Animation, Inc. (TDA). Top Draw Animation is a leading 2D animation business. It produces award-winning animation content for some of the largest international media enterprises. Grom Social Enterprises also includes Grom Educational Services, which has provided web filtering services for K-12 schools, government, as well as private business. Top Draw Animation (TDA), has entered the lucrative 3D animation space in collaboration with a tier-1 entertainment and media giant.

Grom Social Enterprises, Inc. (GROM), closed Friday's trading session at $3.43, up 24.7273%, on 4,620,313 volume with 14,010 trades. The average volume for the last 3 months is 72,310 and the stock's 52-week low/high is $0.155000001/$19.50.

Capstone Companies, Inc. (CAPC)

QualityStocks, MarketBeat, Marketbeat.com, PennyStocks Forever and AllPennyStocks reported earlier on Capstone Companies, Inc. (CAPC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Capstone Companies, Inc. is a designer of innovative LED lighting solutions including power failure lighting. These are for consumers and institutions. Capstone sells its products under the Capstone Lighting and Hoover® HOME LED brands. Capstone Companies is headquartered in Deerfield Beach, Florida. The Company lists on the OTCQB.

Capstone Companies executed a strategy in 2012 to further nourish its product development efforts. The Company made an investment in AC Kinetics, Inc., to confidentially explore and develop certain unique concepts Capstone conceived. Capstone plans to maximize its proprietary technologies through select licensing arrangements.

Capstone Companies’ business strategy is to use its low-cost manufacturing base to provide high-quality consumer products to its customers at a reasonable price, using primarily direct import distribution. Capstone Companies secured the N.A. trademark license for the Hoover® brand for LED lighting products in 2015.

Capstone is a top designer, manufacturer, and marketer of specialty LED lighting solutions. It is also an innovator of other specialty consumer products distributed in numerous countries. These include Australia, Iceland, Japan, Korea, Mexico, North America, South America, Spain, Taiwan and the United Kingdom (UK).

The Company has a selection of product solutions that address consumers’ power failure requirements with a strong, identifiable brand presence. In 2008, Capstone developed and launched its first power failure product, the 6 LED Eco-i-lite Multi-Function LED light. The Company has expanded its product portfolio addressing the necessity for improved safety and security product applications for consumers’ daily life.

Capstone develops, manufactures, and sells a broad variety of stylish, innovative, and user-friendly LED lighting products. These include bath vanity lights, multi-task lights, patented power failure light bulbs, portable accent lighting, and power failure multi-function handheld lights. Products also include power failure plug-in decorative lighting, multi-function nightlights, outdoor LED fixtures, under cabinet lighting, and wireless motion sensor lights.

Capstone Companies, Inc. (CAPC), closed Friday's trading session at $2.19, up 21.6667%, on 210,182 volume with 435 trades. The average volume for the last 3 months is 153,171 and the stock's 52-week low/high is $0.023399999/$3.08999991.

Twin Vee PowerCats, Inc. (TVPC)

QualityStocks reported earlier on Twin Vee PowerCats, Inc. (TVPC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Twin Vee PowerCats, Inc. is one of the largest production-based dual hull boat companies in the United States. It designs, manufactures, and sells recreational and commercial twin-hull power boats under the Twin Vee brand name. Over the past 25 years, It has centered on perfecting the high-speed twin-displacement hull design, also known as a "catamaran powerboat." Twin Vee PowerCats is one of the most recognized brands in the power catamaran industry. The Company has received numerous tributes and awards for industry achievements.

The Company was formerly known as ValueRich, Inc. It changed its name to Twin Vee PowerCats, Inc. in April of 2016. Twin Vee PowerCats is based in Fort Pierce, Florida and the Company lists on the OTC Markets.

Twin Vee PowerCats manufactures American-made products with American marine craftsmen in an American factory. An experienced workforce in Fort Pierce hand-builds Twin Vee boats. Twin Vee PowerCats regularly makes substantial investments into new technology. This augments its traditional hand-built process.

Twin Vee PowerCats recently began redesigning new boat models to ensure that potential boat buyers give twin-hulled boats a chance. Among the re-imagined boats it has developed, Twin Vee launched the 24-foot center console power catamaran in 2019 to enthusiastic acclaim. Center Console Life showcases the boat in its review. Furthermore, Twin Vee PowerCats’ 240 CC was featured by Florida Sportsman Magazine in 2019, stating that the "model certainly hits the mark for style points along with fishability."

Twin Vee PowerCats also announced that because of the unprecedented state of the world because of the COVID-19 (Coronavirus) pandemic, Twin Vee's Management Team is monitoring developments in Florida and the country as a whole.

Mr. Joseph Visconti, President of Twin Vee PowerCats, said, "We want to assure our customers that we are 100 percent on top of this unfortunate situation. We will continue to follow the Center for Disease Control and Prevention for updates and observe any and all prescribed measures for the safety of our employees and the community at large."

Twin Vee PowerCats, Inc. (TVPC), closed Friday's trading session at $0.26, up 33.9619%, on 7,206 volume with 7 trades. The average volume for the last 3 months is 18,415 and the stock's 52-week low/high is $0.018999999/$0.579999983.

Cyber Security 1 AB (CYBNY)

QualityStocks and Stock Market Media Group reported earlier on Cyber Security 1 AB (CYBNY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cyber Security 1 AB is an international leader in Cyber Security. The Company provides cyber resilience solutions and conducts its operations through physical presences in Sweden, South Africa, the United Kingdom (UK), Kenya, Germany, Austria, Turkey, Greece, Italy, the Ukraine and the United Arab Emirates (UAE). The Company formerly went by the name Cognosec AB (publ). It changed its name to Cyber Security 1 AB in July of 2018. Cyber Security 1 AB is based in Stockholm, Sweden. The Company lists on the OTC Markets Group’s OTCQX.

Providing governance, risk, and compliance cybersecurity solutions, Cyber Security 1 provides solutions for client and information systems audit, penetration testing, application security assessment, and security monitoring. In addition, the Company provides solutions for urgent incident response and crisis management, data leakage and loss prevention, and network security and management.

Cyber Security 1 has a growing international footprint, an impressive client list, a flourishing mergers and acquisition (M&A) strategy and in 2019 a newly appointed Chief Executive Officer (CEO). Furthermore, Cyber Security 1 had revenues of 44.54m EUR in 2018 and employed 239 personnel at the end of Q4 2018.

Cyber Security 1 announced earlier this year an exclusive five-year partnership with Formula 1®, the world’s premier motorsport series. It will provide Formula 1® with an assortment of resilient solutions, designed to enhance and secure Formula 1’s infrastructure from potential cyber threats. Cyber Security 1 will work closely with the Information Technology (IT) department at Formula 1®, delivering a number of key projects. This includes consultancy, implementation, and advisory.

Cyber Security 1 recently announced the signing of exclusive Heads of Terms of Agreement pursuant to the acquisition of IntaForensics. Since IntaForensics’ formation in 2006, the business has grown worldwide to provide the widest variety of Digital Forensic and Cyber Security Services from its England headquarters.

IntaForensics is one of the fastest growing Digital Forensic Services providers globally. It is one of a few organizations that possesses the prestigious ISO/IEC 17025 Laboratory Standard. Additionally, it is accredited to ISO/IEC 27001 and ISO 9001. The business is accredited by the PCI Security Standards Council as a Qualified Security Assessor and a PCI Forensics Investigator (QSA, PFI).

Cyber Security 1 AB (CYBNY), closed Friday's trading session at $0.72, up 53.1915%, on 2,085 volume with 3 trades. The average volume for the last 3 months is 2,137 and the stock's 52-week low/high is $0.159999996/$4.9499998.

Australis Capital, Inc. (AUSAF)

QualityStocks and AllPennyStocks reported earlier on Australis Capital, Inc. (AUSAF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Australis adheres to strict investment criteria. The Company focuses on significant near and mid-term high-quality opportunities with strong return potentials. This is while maintaining an unwavering commitment to governance and community.

Australis Capital solely concentrates on creating shareholder value and building transformative companies via early-stage, opportunistic, and diversified investments in the cannabis value chain in the U.S. and internationally. The Company’s partners include Aurora; Rthm Technologies, Inc.; Wagner Dimas; Body and Mind, Inc. (BaM); ShowGrow; Quality Green; Folium Biosciences; Mr. Natural, Inc.; and Green Therapeutics.

Recently, Australis Capital announced it entered into an asset purchase agreement with Green Therapeutics, LLC (GT) and affiliated companies, to acquire its Tsunami™, Provisions™, and GT Flowers cannabis brands, certain operating assets, intellectual property (IP), and the right to assume, complete and expand the construction of a state-of-the-art 55,000 square foot cultivation and production facility in North Las Vegas, Nevada. The 8.9-acre parcel of land in North Las Vegas has the potential to support a 400,000 square foot cultivation and production facility that will be built to the industry recognized Aurora Cannabis standard. This acquisition will include GT's experienced operating team.

In a separate transaction, Australis Capital acquired, from Meridian Companies LLC, an 8.9-acre parcel of land in North Las Vegas in exchange for $2 .93mm USD of its common stock or 3,585,521 Australis common shares where the new cultivation and production facility will be located.

Mr. Scott Dowty, Australis Capital’s Chief Executive Officer, said, "Green Therapeutics and Australis' combined assets, expertise, and network positions our company for tremendous growth and is uniquely positioned with products spanning verticals where long term margins will be insulated. Introducing Mr. Natural's Veteran Affairs registered premium organic strains and proprietary cultivation methodologies to Nevada through a purpose-built facility will serve as the launching ground for a nationally recognized cannabis brand."

Australis Capital also recently announced it appointed Mr. Brent Reuter as its Senior Vice President, Investor Relations and Strategy. Mr. Reuter will concentrate on growth, partnership strategy, as well as investor relations. He comes to Australis Capital with considerable experience driving new revenue growth and managing businesses in the banking and investment sectors, most recently as Principal Investor Relations for Onex Corp, a private equity firm, Vice President of Asset Management for CIBC, and as Managing Director at RBC with roles in Hong Kong and New York.

Australis Capital, Inc. (AUSAF), closed Friday's trading session at $0.2726, up 33.89%, on 618,413 volume with 132 trades. The average volume for the last 3 months is 116,701 and the stock's 52-week low/high is $0.080099999/$0.602699995.

The QualityStocks Company Corner

Cybin Inc. (NEO: CYBN) (OTC: CLXPF)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (OTC: CLXPF).

Cybin (NEO: CYBN) (OTCQB: CLXPF) is a leading biotechnology company focused on progressing psychedelic therapeutics. The company has announced that its Chief Executive Officer Doug Drysdale will participate in a virtual fireside chat at Grizzle Psychedelics Con on June 28, 2021. The fireside chat is slated to begin at 12:30 p.m. ET and will be webcast live at https://ibn.fm/Ec3zS with an archived version available after the event. To view the full press release, visit https://ibn.fm/AhylB

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF), closed Friday's trading session at $2.21, up 6.7633%, on 890,606 volume with 1,320 trades. The average volume for the last 3 months is 415,160 and the stock's 52-week low/high is $0.493800014/$2.23499989.

Recent News

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF)

The QualityStocks Daily Newsletter would like to spotlight TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF).

TAAT ™ GLOBAL ALTERNATIVES INC. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP) (the “Company” or “TAAT ™ ”) is pleased to announce that Peach State Distributor (“PSD”), a wholesaler based in Alpharetta, Georgia, has completely pre-sold its initial purchase order of 15 TAAT™ master cases as part of an initiative to test the state of Georgia (population 10.62 million) as the next potential market for a full-scale launch of TAAT™ as an alternative to tobacco cigarettes. The shipment, which arrived in Alpharetta on Thursday, June 24, 2021, will be allocated for distribution to PSD’s retailer accounts in Georgia and North Carolina, who will become the first official retailers of TAAT™ on the east coast of the United States. These retail placements will complement the existing presence of TAAT™ in more than 250 retailers in the state of Ohio, in addition to the Company’s e-commerce portal which has been selling TAAT™ since February 2021 and avails the product to the majority of smokers aged 21+ in the United States.

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) is a life sciences company dedicated to giving legal-aged smokers the choice to keep the smoking experience that they enjoy with no nicotine and no tobacco.

The key players of TAAT Lifestyle & Wellness are from leading tobacco brands. They are guiding the mission with the company’s proprietary product, TAAT(TM), which uses the company’s proprietary Beyond Tobacco(TM) base material. The base material undergoes a 14-step process to taste and smell just like tobacco and uses a patent-pending refinement technique.

This provides the company with unique opportunities on the global tobacco market, which was estimated at $849 billion in 2019, with approximately 1.3 billion people using tobacco in some form worldwide (https://nnw.fm/bvKFL).

TAAT Lifestyle & Wellness was founded in 2006 and is headquartered in Vancouver, Canada, with operations in Las Vegas, Nevada.

TAAT(TM)

TAAT is a smokable alternative to tobacco cigarettes using the Beyond Tobacco base material, which contains zero tobacco and zero nicotine. The current TAAT offering comes in three varieties: Original, Smooth and Menthol, which were launched during Q4 2020 in Ohio. The company’s Ohio tobacco wholesaler also distributes for major tobacco industry names such as Altria, RJ Reynolds (a subsidiary of British American Tobacco) and ITG.

The TAAT Beyond Tobacco experience was created to replicate the sensory elements of smoking a tobacco cigarette. Market testing in California and Nevada reached a consensus that TAAT products offered no significant differences in experience when compared to tobacco cigarettes, in terms of the following aspects:

  • Visual – the nearly identical product packaging and enhanced smoke volume
  • Auditory – the “crackling” sound of the base material when it is ignited
  • Smell – when burning, TAAT emits a tobacco-like scent
  • Taste – the patent-pending Beyond Tobacco base material undergoes a refinement process that creates a tobacco-like taste
  • Touch – TAAT satisfies the “hand-to-mouth” fixation and motor habits, such as flicking ashes

TAAT Beyond Tobacco Targeting Current Smokers

TAAT Lifestyle & Wellness is currently targeting the market of legal-aged smokers with its proprietary product. The company aims “not to create a new problem, but to solve an existing one.” TAAT Lifestyle & Wellness offers a non-addictive alternative to tobacco, with several competitive advantages making it a promising option on the United States market, such as:

  • Price – TAAT can be offered at a lower price than competing products in the tobacco category, which adds to the propositioned value for current legal-aged smokers.
  • Experience – TAAT appeals to current smokers who wish to give up the tobacco and nicotine but keep the smoking experience they enjoy.
  • Branding/Packaging – TAAT is American-grown and American-made, with its Beyond Tobacco base material serving as a legacy to the combustible tobacco products.

The current alternatives to cigarette smoking do not offer a comparable experience. Previously marketed products, like vaping, proved difficult for some legal-aged smokers to adopt, as the experience was too different from traditional cigarettes.

Market Outlook

In 2016, the United States tobacco market was valued at over $100 billion, a number that’s expected to grow over the next decade (https://nnw.fm/yd8oP). In terms of volume, over 215 billion cigarettes were sold to roughly 34 million adults in the United States in 2018. These numbers represent almost 14% of the adult population. Of those, almost two-thirds smoked more than 15 cigarettes in one day. A standard pack is comprised of 20 cigarettes.

The company’s Beyond Tobacco, as a non-tobacco product, has a price-driven consumer advantage in many states. While state taxes on traditional cigarettes vary, most tend to average around $1.82 per pack. Washington D.C. is on the higher end of the tax spectrum at $4.50 per pack, whereas Missouri is only $0.17 per pack (https://nnw.fm/D3WnT).

TAAT Lifestyle & Wellness estimates that, if one pack of TAAT Beyond Tobacco was sold at 20% of all United States tobacco points of sale, the product would capture 0.25% of the market, the equivalent of approximately 2.7 million cartons of cigarettes per year.

Management Team

Setti Coscarella is the Chief Executive Officer of TAAT Lifestyle & Wellness Ltd. He is experienced in investment banking, private equity and entrepreneurship. In 2017, Mr. Coscarella was the lead strategist for Reduced-Risk Products at Philip Morris International. While there, he worked with thousands of smokers to better understand how to position smoking alternatives, developing programs that could help smokers convert to reduced-risk products. Mr. Coscarella holds an MBA from the Schulich School of Business, specializing in finance, marketing and corporate strategy. He also has a Bachelor of Science in mathematics and physics from the University of Toronto.

Tim Corkum is the company’s Chief Revenue Officer. He has a lengthy history in the tobacco industry, having served 21 years at Philip Morris International. Mr. Corkum has experience leading the international commercialization of combustible cigarettes and working on reduced-risk product offerings. During his 21-year tenure, he held senior positions in business development, sales strategy, key account management and corporate affairs. He holds a BA from Carleton University with a concentration in law.

Joe Deighan is Founder of TAAT Lifestyle & Wellness and oversees research and development. He is the founder of vape liquid ‘JJuice’, created in 2012. JJuice was distributed across all of the United States and in 26 other countries, alongside the private label production that was done for other brands. Mr. Deighan sold JJuice in a cash deal that was valued at over $800,000 in 2017. He currently handles all R&D and production for Beyond Tobacco, knowing the product better than anyone else in the company.

TAAT Lifestyle & Wellness Ltd. (TOBAF), closed Friday's trading session at $2.55, up 4.205%, on 273,250 volume with 501 trades. The average volume for the last 3 months is 166,151 and the stock's 52-week low/high is $0.100000001/$4.73999977.

Recent News

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF)

The QualityStocks Daily Newsletter would like to spotlight Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF).

Nextech (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29), a diversified leading provider of augmented reality (“AR”) experience technologies and services, has closed the previously announced acquisition of Threedy.ai Inc. (“Threedy”). Based in Silicon Valley, California, Threedy is a 3D artificial intelligence (“AI”) modeling for e-commerce company. Upon closing of the acquisition, Nextech issued 3,877,551 common shares in the capital of the company at an agreed value of US$2.45 per share (CA$3.01 per share), for total share consideration of US$9.5 million. To view the full press release, visit https://ibn.fm/ZhMGx

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF), based in Vancouver, Canada, is a leading provider of web-based augmented reality for e-commerce, advertising and virtual events, with technology ranging from simple 3D images to using 360-degree videos. Nextech AR provides businesses with a powerful end-to-end augmented reality platform designed specifically to increase online sales.

The company is currently pursuing four unique verticals with its innovative technology, including:

  • Virtual Conference Platform: Nextech’s advanced Augmented Reality and Video Learning Experience Platform for Events leverages an SaaS model to give organizations the ability to create engaging virtual event management and learning experiences. Automated closed captions and translations for over 64 languages are available. The global virtual events market was valued at $90 billion in 2020 by Grandview Research, and it’s expected to reach more than $400 billion by 2027.
  • ARitize™ for eCommerce: Launched in early 2019, the company’s SaaS platform for webAR in eCommerce serves as a ‘full funnel’ end-to-end e-commerce solution for the AR industry. The solution includes the Aritize360 app for 3D product capture, ‘Try it On’ technology for online apparel, 3D and 360-degree product views, ‘one click buy’ and much more.
  • ARitize™ 3D/AR Advertising Platform: Launched in Q1 2020, this ad platform is being marketed as the industry’s first end-to-end solution leveraging 3D asset creation for 3D/AR ads. In 2019, according to IDC, global advertising spend totaled roughly $725 billion.
  • ARitize™ Hollywood Studios: The studio is in development as a means of producing immersive content using 360-degree videos and augmented reality as primary display platforms.

Unique Marketing Strategy

Nextech AR’s efforts to disrupt the market for web-based augmented reality for e-commerce are supported by a unique go to market strategy. First, the company seeks to build or acquire platforms targeting a number of rapid growth industries, most notably AR, edTech, e-commerce, 3D/AR advertising and virtual & hybrid events.

After identifying these market opportunities, the company seeks to integrate new AR technologies into existing or novel platforms in an effort to secure market share and promote growth. These technologies include WebAR, Human Holograms, 360 Portals, ScreenAR, Genie in the bottle and AiRShow.

Nextech AR then aims to leverage these platforms to land and expand partnerships with a number of blue chip customers. The company’s current customer base includes the likes of Amazon, Johnson & Johnson, ViacomCBS, Toyota and Carnegie Mellon University.

Growth Capital

Nextech AR generates revenue through a software-as-a-service model from technology services, delivery of service revenue and sales of products through e-commerce.

As noted in its latest investor presentation, the company achieved record bookings in Q4 2020 of $7.3 million (estimated), marking a greater than 275% year-over-year increase. The company also realized greater than 235% revenue growth for calendar 2020, reporting $20 million for the 12-month period. Nextech AR attributes its 2020 increase in revenues to the contracts secured with new customers, expanded agreements with existing customers and additional conversions from e-commerce channels.

With its newly launched 3D ad network now bolstering its operations, Nextech AR is projecting revenues in excess of $50 million for 2021.

Recent Company Highlights

  • February 16, 2021: The company announced it has hired Zak Mcleod, formerly of Fastly, as its new Senior Director of Sales – EMEA. The company also announced that Rory Ganness, formerly of Salesforce.com, has joined the Nextech team as Director of Enterprise Sales – North America.
  • February 11, 2021: The company announced the launch of version 2.0 of its AiR Show app, an application that turns top music artists into interactive ‘live’ holograms, providing an immersive and engaging AR experience.
  • February 8, 2021: The company announced the launch of new standardized chat features within its Virtual Experience Platform (VXP) and recently-launched ARoom collaborative streaming solution. Nextech will also offer the chat platform as a stand-alone SaaS service externally, increasing the company’s revenue potential for 2021.
  • January 26, 2021: The company announced, in partnership with ARB Meetings and Events, it has signed a six-figure annual contract to supply its InfernoAR video conferencing and virtual events platform to NAMD.
  • January 25, 2021: The company announced that Strategic Site Selection (SSS), a 15 year old site selection leader in the meeting and events industry, has selected Nextech AR as a preferred channel partner, making Nextech’s industry leading virtual experience platform and services available to SSS clients.
  • January 20, 2021: The company announced that Microsoft’s Azure Cloud Services platform will be a standard offering across its virtual experience platforms and consumer apps, enabling hyper-scalable, secure and immersive events and applications for users.
  • January 15, 2021: The company signed a renewal agreement with Poly with an initial value of $470,000 for a six-month term and the potential for additional revenue after the six months.

Management Team

Evan Gappelberg is CEO and Founder of Nextech AR. He is an experienced operating executive specializing in creating, funding and running hyper-growth startups in both the public and private sectors. Notably, he took Take-Two Interactive Software Inc. (NASDAQ: TTWO) public with a market cap of $30 million and played a key role in guiding its growth to a current market cap of roughly $14 billion. Mr. Gappelberg has extensive experience as both a hands-on operating executive and a public markets professional.

Paul Duffy is the company’s President. He is a serial entrepreneur with over 25 years of experience in successfully starting, expanding, diversifying and selling global technology companies. Mr. Duffy is the creator of the HumaGram and inventor of the patent for Holographic Telepresence over the Internet (TOIP).

Augen Winschel is the COO of Nextech AR. He is an 18-year SAP executive with over 20 years of leadership experience in the areas of business management, business operations, marketing, product management, digital business and enterprise artificial intelligence.

Kashif Malik, CPA, CA, is the company’s CFO. He has over 15 years of financial experience spanning IPOs, M&A activity, corporate restructuring and capital raising. Mr. Malik has worked globally with public and private companies, including Merck & Company Inc. (NYSE: MRK), Real Matters Inc. (TSX: REAL) and Constellation Software Inc. (TSX: CSU). He obtained his Chartered Accountant designation while working at Deloitte.

Hareesh Acchi is the company’s President of 3D/AR Advertising. He is a 20-year Microsoft technology veteran with experience leading digital transformation and scaling businesses and enterprise organizations across the advertising industry.

Nextech AR Solutions Corp. (NEXCF), closed Friday's trading session at $2.21, up 0.108715%, on 99,656 volume with 256 trades. The average volume for the last 3 months is 231,407 and the stock's 52-week low/high is $1.50/$5.41120004.

Recent News

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

The state-legal cannabis industry in America has come a long way despite being just a decade or so old. It has employed hundreds of thousands of individuals, generated billions of dollars in revenue, and filled state coffers with millions of dollars in tax revenue. Cannabis is still considered a Schedule I controlled substance at the federal level, however, and this classification has consistently been a thorn in the sector’s side. Some form of cannabis policy reform at the federal level would be a great help to the entire industry, including Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF), as some of the regulatory conflicts between state law and federal law would be clarified.

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

  • Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
  • High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
  • Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

  • A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
  • Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
  • Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Friday's trading session at $0.9199, up 2.2111%, on 310,747 volume with 253 trades. The average volume for the last 3 months is 395,768 and the stock's 52-week low/high is $0.330000013/$1.64999997.

Recent News

Save Foods Inc. (NASDAQ: SVFD)

The QualityStocks Daily Newsletter would like to spotlight Save Foods Inc. (NASDAQ: SVFD).

Save Foods (NASDAQ: SVFD) is an agri-food tech company focused on developing and bringing to market eco-friendly products specifically designed to ensure food safety and extend the shelf life of fresh fruits and vegetables. The company is dedicated to providing solutions that overcome two of the most significant challenges faced by the industry, which are food waste/loss and food safety. “Save Foods’ products use all-natural ingredients to protect fresh produce from microbial spoilage and pathogens with zero toxicity. To view the full article, visit https://ibn.fm/rqhIz

Save Foods Inc. (NASDAQ: SVFD) is an agri-food tech company focused on developing and selling eco-friendly products specifically designed to ensure food safety and extend the shelf life of fresh fruits and vegetables. The company is focused on addressing two of the most significant challenges faced by the industry: (1) food waste and loss, and (2) food safety.

Fungi like mold and yeast, as well as foodborne pathogens, are typically responsible for fresh produce spoilage and foodborne illness. Save Foods’ integrated solutions improve safety, freshness and quality every step of the way, from field to fork. The company’s natural products control human and plant pathogens, allowing growers, packers and food retailers to reduce waste and boost revenues. More food ends up on consumers’ plates, and less ends up in landfills.

Save Foods’ products use all-natural ingredients to protect fresh produce from microbial spoilage and pathogens with zero toxicity. The company’s treatments leave no harmful residues on produce or in the environment and maintain product freshness over time. Fresh produce treated with Save Foods’ products can already be found in supermarket chains across the U.S. and Europe. Those chains have reported that the company’s products are reducing fruit spoilage by 50% on average at the retail level. With no need for additional steps in the treatment process nor special equipment, Save Foods’ products are easy to implement and come in versatile applications suitable for the different stakeholders along the food supply chain.

Initial applications for the company’s offerings include post-harvest treatments in fruit and vegetable packing houses that process citrus, avocados, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of chemicals and their residues, Save Foods’ products not only prolong shelf life; they also ensure safe, natural and healthy food. Save Foods has the first green products that could realistically replace the different chemicals used today in food treatment while controlling waste and food safety.

Products & Technology

  • SavePROTECT or PeroStar, a processing aid added to fruit and vegetable wash water and used in post-harvest treatment;
  • SF3HS and SF3H, post-harvest treartment solutions to control both plant and foodborne pathogens;
  • SpuDefender, for controlling post-harvest potato sprouts; and
  • FreshPROTECT, for controlling spoilage microorganisms on post-harvest citrus.

Save Foods’ products are based on a proprietary blend of food acids which have a synergistic effect when combined with certain types of sanitizers and fungicides at low concentrations in a non-organic setting. The combination eliminates fungicide residues or reduces them to levels below the established Maximum Residue Levels (MRLs). The company’s fruit and vegetable wash is odorless and does not irritate human eyes, skin or airways. Save Foods’ blend does not leave any residues of toxicological concern on the treated surface of produce, and all its ingredients are classified by the U.S. Food and Drug Administration (FDA) as Generally Recognized As Safe (GRAS). There are 7 patent families related to Save Foods’ technology.

Applications

The company’s products have been commercially validated on citrus, mangos, avocados, pears, bell peppers, microgreens and various fresh cut vegetables. Save Foods is in the validation process for bananas, apples, figs, berries, lettuce, papayas and more. The company is also validating the efficacy of its products for pre-harvest treatment, starting with citrus trees.

Market Outlook

The world population is expected to grow to almost 10 billion by 2050, boosting current agricultural demand by some 50%. Providing healthy and safe food for the world’s population is one of the biggest challenges of the 21st century.

Globally, around 664 million tons of fresh fruits and vegetables are lost every year from field to fork, wasted by spoilage, and almost one in 10 people globally falls ill every year from eating contaminated food, with an estimated resulting cost around $90 billion.

Disposing of all that wasted food requires additional expense and harms the environment with resulting greenhouse gas emissions. The post-harvest food treatment market was valued at $1.5 billion in 2019 and is expected to grow to $2.3 billion by 2026, achieving a CAGR of 6.5%.

Management Team

David Palach is CEO of Save Foods. He spent over a decade with Intel Israel, where his last position was Manager of Business Development for Israel and Europe. Prior to that, he served as a controller of two of Intel’s largest factories in Israel, where he supervised a budget of over $1 billion. He also served as the CEO of B-Pure Corporation Ltd., a management and maintenance company involved in protecting and improving the environment. During his tenure, he helped turn around several struggling subsidiaries and made them profitable.

Vered Raz Avayo is the company’s CFO. Before joining SaveFoods in 2018, she spent more than 10 years as CFO at LGC, the Leviev Group of Companies. She has operated her own financial and business consultancy and has served as a director for a number of public companies in Israel.

Dan Sztybel is CEO of SaveFoods Ltd., the Israeli subsidiary of Save Foods Inc. He previously led the Life Sciences Advisory at EY Israel and early on recognized the potential of Israel as a center of innovation in the digital health space. He has been an adviser on digital health strategy to large pharmaceutical companies and is a cofounder of MyndYou, a digital health start-up focusing on cognitive impairment. He is also a co-founder of the DigitalHealth.il conference, the largest digital health conference in Israel.

Dr. Neta Matis is Vice President of R&D at Save Foods Ltd the Israeli subsidiary of Save Foods Inc . She holds a Ph.D. in organic chemistry and an MBA from Tel Aviv University. Prior to joining Save Foods in 2019, she held multiple research chemist and product development roles at Verdia Inc. and its parent company, Helsinki-based Stora Enso Oyj.

Nimrod Ben Yehuda is the founder and CTO of Save Foods Ltd. He was previously the CEO/CTO of Swissteril Water Purifications Ltd. He has also been CEO at Nir Ecology Ltd., and was Joint-CEO at NitroJet Ltd.

Dr. Art Dawson is the U.S. Business Manager for SaveFoods Inc. He has been president of The Dawson Company, which focuses on creating sales opportunities for new agricultural technologies, previously Dr. Dawson held senior industry positions like General Manager Worldwide of the Decco , the Post Harvest Division for Elf Atochem. He holds a Ph.D. in Plant Physiology from UC Riverside and is licensed in California as an agricultural Pest Control Advisor.

Save Foods Inc. (SVFD), closed Friday's trading session at $9.2154, up 0.604804%, on 6,817 volume with 26 trades. The average volume for the last 3 months is 11,451 and the stock's 52-week low/high is $1.75/$30.1000003.

Recent News

Vivos Therapeutics Inc. (NASDAQ: VVOS)

The QualityStocks Daily Newsletter would like to spotlight Vivos Therapeutics Inc. (NASDAQ: VVOS).

Since its inception, Vivos Therapeutics (NASDAQ: VVOS) has been a trailblazer in diagnosing and treating mild-to-moderate Obstructive Sleep Apnea (“OSA”). Its main product — Vivos System — results from years of research and has been instrumental in treating the condition among adults. Dr. G. Dave Singh, the personality behind Vivos Therapeutics, shares the process behind Vivos System’s innovation and the scientific and biological foundation of the product in his new book titled Pneumopedics and Craniofacial Epigenetics. He details his research’s progress and Vivo Therapeutics’ achievements over the years.

Headquartered in Denver, Colorado, Vivos Therapeutics Inc. (NASDAQ: VVOS) is an emerging global leader in the treatment of mild-to-moderate obstructive sleep apnea (OSA), a debilitating condition affecting nearly 1 billion people worldwide. The company utilizes proprietary, ground-breaking technology, a proven go-to-market strategy, and a powerful executive team dedicated to changing the face of health care by helping people of all ages properly breathe and sleep.

At the core of Vivos’ mission to rid the world of mild-to-moderate OSA is the Vivos System®, a revolutionary clinical breakthrough in the treatment of mild-to-moderate sleep apnea often caused by craniofacial anatomy development. The Vivos System® multidisciplinary treatment protocol involves collaboration between physicians, specially-trained dentists who have completed advanced training in craniofacial sleep medicine, and other ancillary health care providers.

In support of its growth strategy, Vivos has established contract manufacturing facilities in the U.S., Canada and Asia.

Market & Technology Overview

Craniofacial developmental deficiencies, such as underdeveloped upper and lower jaws, are among the leading causes of OSA. According to a 2019 analysis from researchers at the University of California, San Diego, an estimated 81 million adults in North and South America suffer from moderate to severe OSA. The United States has the highest amount of these patients, with approximately 54 million adults affected, according to the report.

Registered with the FDA as a Specification Developer, Vivos develops and markets a number of oral appliances. Its technology represents the first non-surgical, non-invasive and cost-effective treatment for the estimated hundreds of millions of people globally who suffer from mild-to-moderate OSA.

Vivos integrates its specially designed, customized appliances into a patient-specific, multi-disciplinary clinical protocol, giving trained dental and medical providers the tools and roadmap needed to address certain craniofacial conditions that studies have shown to be associated with sleep-disordered breathing—including mild-to-moderate OSA.

The system’s treatment protocol involves collaboration between physicians, specially trained dentists who have received advanced training in craniofacial sleep medicine, and additional health care providers. Vivos-trained clinicians can be found in almost every major city in the U.S. and in many countries throughout the world. The company’s oral appliances have shown to be effective in over 15,000 patients successfully treated worldwide by approximately 1,200 trained dentists.

A New Paradigm in Sleep Medicine

Vivos’ proprietary system poses the potential to be the biggest breakthrough in the treatment of mild-to-moderate OSA since CPAP.

The Vivos System has been specifically designed to promote the proper growth and development of the hard and soft tissues surrounding and comprising the oral cavity, nasal cavity, upper and lower jaws, and other tissues which together form and shape the upper airway. As these areas develop more fully using the Vivos System, a patient’s airway typically widens and expands, enabling them to breathe properly through their nose. With a more open and less obstructed airway, and easier nocturnal breathing, the symptoms of SDB tend to diminish over time, and patients often report they no longer suffer from the adverse effects of SDB or OSA.

Use of the Vivos System is variable and case dependent, but typically recommended to be worn daily for 12 to 16 hours starting in the early evening and continuing overnight. The total treatment time typically ranges from 12 to 24 months, with 18 months being the approximate mean treatment time.

Biomimetic Oral Appliance

Vivos Therapeutics believes that the Vivos System technology represents the first non-surgical, non-invasive and cost-effective treatment for people with mild-to-moderate OSA.

Combining technologies and protocols that can alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can significantly reduce symptoms and conditions associated with mild-to-moderate OSA.

The Vivos System treatment is typically less than $10,000 and is often reimbursable by medical insurance as an out-of-network benefit.

A potentially serious medical problem with an alternative treatment therapy available in the dental office.

Hard and soft tissues of the craniofacial complex can be non-surgically enhanced using the proprietary Vivos® System devices and clinical protocols.

Leadership

R. Kirk Huntsman – CEO, Director
With experience in strategic development, technology acquisition and product planning, key talent recruitment, and target market prioritization, Huntsman brings a broad vision paired with leadership and strategic planning skills. He has significant start-up experience in a diverse range of market sectors, including medical devices, dental management, dental practice valuations and transitions, multi-location retail, financial and capital formation, consulting, outsourced services, imports and exports (China), medical services, and software and technology.

Dr. Dave Singh – Founder, Director
A doctor three times over in dental medicine, craniofacial development, and orthodontics, Dr. Singh was educated primarily in England and has lectured in North America, Europe, Asia, and Africa. The Global Summits Institute recently named Dr. Singh as one of the Top 100 Doctors in Dentistry.

Vivos Therapeutics Inc. (NASDAQ: VVOS), closed Friday's trading session at $4.99, up 0.808081%, on 104,692 volume with 683 trades. The average volume for the last 3 months is 191,910 and the stock's 52-week low/high is $4.8499999/$14.4099998.

Recent News

Grapefruit USA Inc. (OTCQB: GPFT)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit USA Inc. (OTCQB: GPFT).

Grapefruit USA (OTCQB: GPFT), a premiere, fully licensed, California-based cannabis company, is providing clarification regarding its previously announced potential acquisition transaction by a Canadian cannabis company (https://cnw.fm/2xIyE). Earlier this year, Grapefruit announced that it had been approached by a Canadian cannabis company to enter into discussions concerning a potential acquisition transaction (https://cnw.fm/OBDib).

Grapefruit USA Inc. (OTCQB: GPFT) is a Delaware corporation that is a fully licensed premier cannabis manufacturer and distributor in the legal cannabis marketplace with its own patented and branded line of products.

The company manufactures its patented product line and distributes it, along with other cannabis products, to all properly licensed cannabis product businesses.

Grapefruit is the only cannabis company that has harnessed cutting edge science and technology to bring patented, truly disruptive products to the medicinal and recreational cannabis marketplace, fundamentally changing the way individuals use THC, CBDs and hemp-derived CBDs and capitalizing on the rise in demand for these unique products.

Headquartered in Los Angeles, California, the company has held licensing in the state for manufacturing and distributing cannabis since 2018. Grapefruit currently owns and operates a California-licensed cannabis extraction laboratory and a licensed wholesale distribution facility in the Coachillin’ Canna-Business Park near Palm Springs, California. Grapefruit is managed by a team of experts who possess the experience, skills and resources required to succeed in the competitive cannabis marketplace.

Hourglass™ Topical Delivery Cream

Grapefruit’s patented Hourglass™ topical delivery cream has solved the previously insurmountable difficulties of efficient skin absorption of THC and other cannabinoids.

Hourglass™ allows users to experience a sustained and holistic delivery of THC/cannabinoids providing “the entourage effect” following initial application to the skin. Additional applications may be made confidently and discreetly at the user’s discretion. There simply is no other product on the planet which successfully utilizes a patented time release THC and CBD delivery mechanism to deliver the holistic benefits of cannabis to those who need it.*

Hourglass™ is a unique, highly concentrated full spectrum time-release topical delivery cream that releases a holistic amount of THC, along with a wide range of cannabinoids (or just CBD), over a four- to eight-hour period.* The formula then comes off through the natural sloughing process of dead skin cells. Hourglass provides many holistic benefits, all of which promote health and wellness as it’s number one goal.

Hourglass™ provides users with an entourage effect of THC plus a wide range of cannabinoids, including CBD, Cannabinol (CBN), Cannabigerol (CBG), Delta-8, Tetrahydrocannabivarin (THCV), and Cannabielsoin (CBE) in a Patchless Patch™ system that is novel and proprietary to the company.

Hourglass™ Topical Delivery Cream has fundamentally changed the way individuals use THC and cannabinoids to obtain their holistic benefits.* As a result, smoking cannabis or hemp flowers and orally consuming edibles, which are metabolized in the gut and liver resulting in uneven reactions, are no longer the exclusive ways to receive both the medicinal and recreational benefits of THC/cannabinoids.* Now for the first time in history, there is an effective, easy to use third choice – Hourglass™ by Grapefruit.

*This product is not regulated by the FDA and is not intended to cure, mitigate, treat or prevent disease.

Grapefruit Cannabis Services

Grapefruit distributes cannabis flower and cannabis products, including its own proprietary products, as well as a wide range of services, to other properly licensed cannabis product businesses. These products and services include:

  • Distribution – As a premier licensed distributor, Grapefruit handles the distribution of all-things cannabis throughout California, specializing in bulk AAA exotic indoor flowers sourced from farms located in the state. The wholesale distribution arm facilitates flowers, fresh and dry frozen, and oil transactions in bulk wholesale form. Its wholesale distribution arm distributes its patented Hourglass™ topical delivery cream.
  • Manufacturing – The company owns and operates a fully licensed and compliant ethanol extraction lab that produces a high-quality distillate. This THC Honey Oil distillate is a universal product used in everything, including infused edibles, tinctures, creams and even vape cartridges. Its patented Hourglass™ cream is also manufactured exclusively at Grapefruit’s Coachillin lab facility by highly trained Grapefruit personnel.
  • Hourglass™ Topical THC+CBD Delivery Cream – The company’s patented Hourglass™ Topical Delivery Cream has solved the inherent difficulties of efficient skin absorption of THC and cannabinoids such as CBD, CBN, CBG and CBC, as well as hemp-derived CBDs and cannabinoids. Hourglass™ is a truly novel and disruptive delivery technology which fundamentally changes the way individuals will use THC and CBD to obtain their holistic benefits.*
  • Rainbow Dreams – Rainbow Dreams is the company’s lifestyle brand designed for the recreational cannabis marketplace. The brand captures the party-mode of the 1970s and offers vape carts with unique cannabis strains and natural flavors. The product fulfills an important marketplace niche – a top-shelf product that is competitively priced.

Market Outlook

The global cannabis market was valued at $10.6 billion in 2018. During the forecast period from 2019 to 2026, the market is expected to grow at a CAGR of 32.92%, reaching a projected value of $97.35 billion by the end of 2026 (https://nnw.fm/eTMSX).

Cannabis legalization has been gaining momentum around the world. Grapefruit is currently in a position to disrupt the industry – both the medicinal and recreational sectors – with proprietary products and manufacturing processes that harness the power of cutting-edge science and technology.

Management Team

Bradley J. Yourist is the Chief Executive Officer of Grapefruit. Mr. Yourist has been a follower of the medical cannabis market since the late 1990s, which allows him to understand the distribution model and the legal issues facing the market. He has also seen the benefit of cannabinoids in the medical industry. He understands the planning and operations of Grapefruit’s cannabis distribution arm and extraction lab and was instrumental in the planning for the facility.

Daniel J. Yourist is the Chief Operating Officer of Grapefruit. He is a licensed attorney in the state of California and a Real Estate Broker. Mr. Yourist is a licensing expert in the cannabis space and has gained extensive experience in all areas of managing a cannabis business in California. He ensures that every aspect of the company is run in accordance with state and local cannabis laws and regulations.

Grapefruit USA Inc. (OTCQB: GPFT), closed Friday's trading session at $0.055, up 1.9085%, on 1,563,175 volume with 114 trades. The average volume for the last 3 months is 750,375 and the stock's 52-week low/high is $0.013624999/$0.310000002.

Recent News

VistaGen Therapeutics Inc. (NASDAQ: VTGN)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics Inc. (NASDAQ: VTGN).

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will host a conference call to provide a business update and discuss financial and operating results for its fiscal year ended March 31, 2021. The call is scheduled to begin at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on Tuesday, June 29, 2021. VistaGen CEO Shawn Singh and other members of the company’s management team will host the call and provide an update on VistaGen’s recent developments, milestones during its 2021 fiscal year, as well as discuss certain target milestones and future goals. Interested parties may join by dialing 1-877-407-9716 (U.S./Toll-Free) or 1-201-493-6779 (International/Toll) and entering conference ID: 13720908. A live audio webcast of the conference call will also be available at https://ibn.fm/WtQNv. To view the full press release, visit https://ibn.fm/FiOIu

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

  • Adjustment Disorder with Anxiety
  • Generalized Anxiety Disorder
  • Postpartum Anxiety
  • Perioperative Anxiety
  • Panic Disorder
  • PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

  • Postpartum Depression
  • Treatment-resistant Depression
  • Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (NMDAR) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

  • Major Depressive Disorder
  • Neuropathic Pain
  • Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
  • Epilepsy
  • Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://nnw.fm/K2m0s) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://nnw.fm/oftNb).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

H. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

VistaGen Therapeutics Inc. (NASDAQ: VTGN), closed Friday's trading session at $2.65, up 0.760456%, on 24,616,812 volume with 15,000 trades. The average volume for the last 3 months is 2.227M and the stock's 52-week low/high is $0.460000008/$3.18000006.

Recent News

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF).

Gold, which is sometimes referred to as the yellow metal, and silver are considered to be precious metals because of their reflectivity. Of the two metals though, silver reflects 95% of white light, which makes it suitable for use in jewelry. Silver is actually the shiniest metal, with aluminum coming in second, reflecting 90% of white light. However, despite coming in second, it is aluminum that is used by NASA in its Hubble Space Telescope. Players in precious metals segment such as GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) may benefit whether it is gold in pole position or silver becomes a favorite among investors.

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: GHVNF), closed Friday's trading session at $0.4644, up 11.5006%, on 36,900 volume with 15 trades. The average volume for the last 3 months is 80,226 and the stock's 52-week low/high is $0.170000001/$0.870000004.

Recent News

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) (the “Company” or “PLUS”) has filed an Early Warning Report (the “Report”) as required by National Instrument 62-103 on behalf of Matt Schmidt regarding his holdings in the Company in connection with an acquisition of Class B Common Shares (“Class B Subordinate Voting Shares”) issued pursuant to Restricted Stock Units awarded to Mr. Schmidt (the “Issuance”).

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Friday's trading session at $0.3994, off by 0.770186%, on 90,265 volume with 30 trades. The average volume for the last 3 months is 81,825 and the stock's 52-week low/high is $0.324999988/$1.14999997.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global (OTCQB: SHRG) has announced that its wholly owned subsidiary, the Happy Co., is preparing to launch into 21 European countries with its exclusive, high-quality products. The Happy Co. is a leading producer and distributor of nootropic, functional beverage products with a focus on health and wellness.

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed Friday's trading session at $0.145, up 14.9881%, on 110,784 volume with 19 trades. The average volume for the last 3 months is 104,439 and the stock's 52-week low/high is $0.075000002/$0.730000019.

Recent News

StorEn Technologies Inc.

The QualityStocks Daily Newsletter would like to spotlight StorEn Technologies Inc.

StorEn Technologies is building a reputation in the development of evolutionary vanadium flow batteries and the future of energy storage. StorEn’s products are designed leveraging the company’s technology that delivers higher performance at lower cost, resulting in more efficient, environmentally friendly and cost-effective energy storage. “Citing a case study comparing a StorEn vanadium flow battery with lithium batteries, StorEn came out the clear winner,” reports a recent article on the company’s positioning. “StorEn’s battery life is 25 years, or 15,000 equivalent full cycles, or ‘EFCs’ (at 100% discharge), compared to lithium batteries (e.g., Tesla’s Powerwall is warranted for 10 years at 70% capacity). StorEn delivers 20 or 30kWh to Tesla’s 13.5kWh levels. StorEn’s product is 100% recyclable with a 100% reusable electrolyte, while the recycling of lithium batteries is complicated and expensive.” To view the full article, visit https://ibn.fm/oubYq

StorEn Technologies Inc. delivers proprietary vanadium flow batteries aimed at revolutionizing the world of residential and industrial energy storage. With an expected life of 25 years and more than 15,000 cycles, the company’s batteries satisfy market demand for efficient, durable and cost-effective energy storage, enabling self-consumption of self-produced electricity and the transition toward a carbon-free economy.

The company is currently accepting investments through a Reg A+ offering on StartEngine. For more information, view the company’s Offering Circular. To date, StorEn has raised more than $6.7 million from over 5,000 investors on the crowdfunding platform, along with venture capital from the ANYSEED Fund.

StorEn’s growing intellectual property portfolio currently features four international PCT patents and five trademarks, securing its innovative IP in all major regions and countries in the world.

A Disruptive Approach to Energy Storage

StorEn’s patent-pending all-vanadium flow battery technology offers a variety of benefits over existing lithium and lead acid batteries, including:

  • Eco-Friendly: StorEn vanadium flow batteries are 100% recyclable, featuring a 100% reusable electrolyte and low GHGs emissions.
  • Safe: The company’s batteries are both non-flammable and non-explosive.
  • Cost Effective: StorEn’s cost/kWh is comparable to that of lithium batteries, but its cost/cycle is up to four times lower than lithium batteries, thanks to the exceptional duration of over 25 years or 15,000 cycles.
  • Efficient: The company’s vanadium flow battery technology offers the highest power density thanks to MULTIGRIDS™, +35% in energy storage capacity with the same volume and +5% round-trip efficiency in harsh climate thanks to its proprietary THERMASTABLE™ geothermal design. StorEn’s solution is also virtually maintenance-free, leveraging its proprietary RESAFE™ and EQUILEVELS™ technologies.

StorEn batteries are modular and configurable in either 20kWh or 30kWh versions sharing the same Power Module, ensuring that customers only pay for the energy capacity they really need. The ability to connect additional modules allows for maximum flexibility.

Traction in the Market

To date, the total investment in the company’s technology has exceeded $2 million, and it is already putting these efforts to work. StorEn secured a $500,000 order in Australia to provide 30 kWh StorEn vanadium flow batteries to a renewable hydrogen plant at Queensland University of Technology (QUT), where researchers will develop safety standards for the future use of vanadium flow batteries. The first battery – the first of its kind in Australia – was installed in Brisbane in November 2020 at the National Battery Testing Centre (NBTC), a flagship project of the Future Battery Industries CRC. Additional units are being manufactured.

StorEn has also entered into a supply chain deal with Multicom Resources, an Australian mining company which is the owner of two vanadium mines. Through this agreement, StorEn has secured the exclusive availability of vanadium for up to 20 years with either a price cap or at market price, whichever is lower.

Capitalizing on the Australian government’s support to fulfil the country’s energy storage opportunity, Multicom’s subsidiary, Freedom Energy, has agreed to assemble StorEn batteries within Australia and distribute them widely across the wider Asia Pacific region. In addition to an initial pilot plant, Multicom has completed a concept design for a full-scale manufacturing facility for StorEn batteries.

Market Opportunity

The shift to renewable energy sources is on, with governments around the globe discussing and implementing initiatives to reduce dependence on fossil fuels. McKinsey & Company research suggests that, by 2035, more than 50% of global power generation will come from renewable sources.

Spurred on by this transition, demand for reliable energy storage systems is expected to attain exponential growth in the coming years, positively influencing the energy storage industry landscape, according to Grand View Research.

Data from Fortune Business Insights projects that the global battery energy storage market will reach $19.74 billion by 2027, recording a CAGR of 20.4% from 2020 to 2027. The research firm suggests that improving access to electricity across the globe will be a prominent trend shaping the growth trajectory of this market, which is particularly noteworthy for StorEn and its TITANstack™ grid-scale energy storage solution.

Over a billion people still do not have access to electricity. The electrification of these unserved communities can become a reality with mini grids, using solar plus energy storage. StorEn’s vanadium flow batteries could be a key technology toward providing universal access to affordable, longer lasting and dependable energy. In support this critical mission, StorEn Technologies is a member of the Alliance for Rural Electrification and the Global Off-Grid Lighting Association.

Management Team

StorEn is led by an executive team with decades of experience in the vanadium flow battery industry.

Founder Carlo Brovero has served as the company’s chief executive officer, treasurer and director since its inception in January 2017. From 2013 to 2019, Mr. Brovero served as a consultant for eCaral Ltd., a management consulting firm. From 2013 to 2015, he served as an advisory board member for Proxhima S.r.l., a vanadium flow battery company, which was sold to the Gala Group, a utility listed on the Milan Stock Exchange. From 2010 to 2016, Mr. Brovero served as International Sales and Marketing Director for iVis Technologies, the manufacturer of an excimer laser therapeutic and refractive platform for corneal surgery. He holds an MBA from Aston University in Birmingham, UK.

Founder Angelo D’Anzi has served as StorEn’s chief technology officer and director since the company’s inception. He is primarily responsible for the technical development of StorEn’s products. Since May 2018, Mr. D’Anzi has also served as a director of Arco Fuel Cells S.r.l., where he is responsible for the company’s fuel cell technical development activities. Mr. D’Anzi co-founded vanadium flow battery company Proxhima in 2013. In 2000, he founded ROEN-EST, a fuel cell company that was eventually acquired by the Morphic Group, a cleantech holding company listed on the Stockholm Stock Exchange. Mr. D’Anzi holds 14 international patents and received the 2003 Sapio Award in the Energy and Transportation category. He holds an MBA from the LUISS Business School in Rome.

Founder Gabriele Colombo has served as secretary of StorEn since its inception. Since 2012, he has also served in various roles ranging from regional manager to CEO with Leonardo Hispania S.A., a subsidiary of the Leonardo Group of Italy, an aerospace, defense and security conglomerate. Mr. Colombo co-founded vanadium flow battery company Proxhima in 2013. He holds an honors degree in computer engineering from the University of Pisa and a master’s degree in business leadership from the University of Genova.


Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public comspanies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.